SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2007 / Cilt: 41 - Sayı: 4

Effectiveness of the 5% Imiquimod cream in the tratment of basal cell carcinoma

Bazal hücreli kaesinoma tedavisinde %5 '' ımiquimod''kremin etkinliği

Gül BARUT
Deniz BALABAN
Kadriye KOÇ
Funda GÜNERİ
Reyhan ÇELİK
Pages
129–132
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We conclude that, complete response rates were 70% with imiquimod cream in the treatment of basal cell carcinoma and this medication is an effective treatment option. (Turkderm 2007; 41: 129-32)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Basal cell carcinoma is one of the most common skin carcinomas.There are many treatment methods which are assosiated with several advantages and disadvantages.Imiquimod is an agonist of TLR-7 (toll-like receptor-7) and is believed to act by inducing cytokines,although the exact mechanism of action is still uncertain.
📊
Key Findings & Data:Our aim was to evaluate the effect of 5% imiquimod cream in the treatment of basal cell carcinoma.
💡
Conclusion & Impact:Conclusion: We conclude that, complete response rates were 70% with imiquimod cream in the treatment of basal cell carcinoma and this medication is an effective treatment option. (Turkderm 2007; 41: 129-32)
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

Basal cell carcinoma is one of the most common skin carcinomas.There are many treatment methods which are assosiated with several advantages and disadvantages.Imiquimod is an agonist of TLR-7 (toll-like receptor-7) and is believed to act by inducing cytokines,although the exact mechanism of action is still uncertain. Our aim was to evaluate the effect of 5% imiquimod cream in the treatment of basal cell carcinoma. Materials and Methods: Patients (n=20) were treated with imiquimod 3 times a week,once daily for 24 weeks and evaluated for weekly response to imiquimod. Conclusion: We conclude that, complete response rates were 70% with imiquimod cream in the treatment of basal cell carcinoma and this medication is an effective treatment option. (Turkderm 2007; 41: 129-32)

Özet

Bazal hücreli karsinoma en yayg›n deri kanserlerinden biridir. Tedavisinde birçok yöntem olmakla birlikte (cerrahi, Mohs cerrahisi, elektrodessikasyon, kriyocerrahi, radyoterapi, fotodinamik tedavi gibi), hepsinin baz› avantaj ve dezavantajlar› bulunmaktad›r. Son zamanlarda bu konuda bir immün cevap düzenleyici olan “imiquimod” %5 krem (Aldara) popüler hale gelmifltir. Bu, TLR-7 (toll-like reseptör 7) üzerinden etki yaparak birçok sitokini uyarmak suretiyle antiviral ve antitümöral etki gösteren bir maddedir. Bu çal›flmada, bazal hücreli karsinoma tedavisinde “imiquimod” etkinli¤ini de¤erlendirmeyi amaçlad›k. Gereç ve Yöntem: Hastalar (n=20) 24 hafta boyunca haftada 3 kez, günde bir defa olmak üzere imiquimod kremle tedavi edildiler. Sonuç: Bazal hücreli karsinoma tedavisinde imiquimod % 5 krem ile % 70 oran›nda baflar› elde ettik. Bu yöntem etkili bir tedavi seçene¤idir. (Turkderm 2007; 41: 129-32)

🔖

Cite This Article

BARUT, G., BALABAN, D., KOÇ, K., GÜNERİ, F., ÇELİK, R. (2022). Effectiveness of the 5% Imiquimod cream in the tratment of basal cell carcinoma. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 41 - Sayı: 4, 129–132. https://ajindex.com/articles/622146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Drehs MM, Bolden FC: Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature. Dermatol Surg 2002;28:427-9
  2. Vidal D, Matias Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004;29:518-25
  3. Burns C.A:Imiquimod fort he treatment of skin cancer.Dermatol Clin 2005;23:151-64
  4. Huber A, Huber J, Skinner RB: Topical imiquimod treatment for nodular basal cell carcinomas: An open-label series. Dermatol Surg 2004;30:429-30
  5. Cowen E, Mercurio MG, Gaspari AA: An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. J Am Acad Dermatol 2002;47(4 suppl.):240-8
  6. Dahl MV: Imiquimod: an immun response modifier.J Am Acad Dermatol 2000;43 (1 pt 2):6-11
  7. Navi D,Huntley A:Imiquimod 5% cream and the treatment of cutaneous malignancy. Dermatol Online J 2004;15;10:4
  8. Dummer R,Urosevic M, Kemf W:Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol 2003;149 (suppl.66):57-8
  9. Beutner KR, Geisse JK, Helman D: Therapeutic response modifier imiquimod 5% cream.J Am Acad Dermatol 1999; 41:1002-7
  10. Marks R, Gebauer K, Shumack S: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6 week dose –response trial. J Am Acad Dermatol 2001;44:807-13
  11. Geisse JK, Rich P, Pandya A: Imiquimod 5% cream fort he treatment of superficial basal cell carcinoma:a double blind, randomised, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-8
  12. Lang PG, Maize JC: Basal cell carcinoma. Cancer of the skin. Ed. Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS. Birinci Bask›. Philadelphia, Elsevier inc, 2005;101-25
  13. Shumack S, Robinson J, Kossard S: Efficacy of topical 5% imiquimod cream fort the treatment of nodular basal cell carcinoma. Arch Dermatol 2002; 138:1165-71.